MGMa. Teresita Gabriel

Ma. Teresita Gabriel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ma. Teresita Gabriel has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The efficacy and safety of Makabuhay (Tinospora rumpphi) 25% cream vs hydrocortisone 1% cream in the management of mosquito bite reactions: randomized, double blind controlled trial (Preprint)

    by Julius Garcia Gatmaitan, Jolene Kristine Garcia Gatmaitan-Dumlao, Johannes Dayrit, Ma. Teresita Gabriel

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Most insect bite reactions resolve spontaneously, but the inflammation and pruritus induced have shown to decrease quality of life. Previous studies have shown potential anti-inflammatory properties of Tinospora rumpphi. Objective: To assess the efficacy and safety of Tinospora rumpphi 25% cream versus hydrocortisone 1% cream in the management of local cutaneous reactions caused by mosquito bites. Methods: This was a randomized double-blind study. Participants were exposed to sterile non-infectious mosquito (Aedes aegyptii) for 5-10 minutes to elicit cutaneous lesions. Tinospora 25% cream or hydrocortisone 1% cream were applied twice daily throughout the 7-day study period. Results: Fifty-eight participants were randomized to receive Tinospora cream (n=29) or hydrocortisone cream (n=29). All participants completed follow-up. There was a significant decrease in lesion size in both groups from the first 15 minutes to day 7 (P=.0001). Comparing the lesion size in both groups, there was a statistically significant decrease in lesion size on the 1st hour (P=.0034) and after 24 hours (P =.0268). On day 1, 10.3% of participants in the hydrocortisone group and 6.9 % in the Tinospora group experienced complete resolution. On day 3, all participants experienced complete resolution. No adverse effects were documented. Conclusions: Tinospora 25% cream is effective, safe, and comparable to hydrocortisone 1% cream as an anti-inflammatory agent for mosquito bite reactions, based on decrease in lesion size, proportion of participants with complete resolution of wheals and improvement in pruritus intensity score using visual analog scale. Long-term safety studies are recommended. Clinical Trial: The study was approved by the Institutional Board Review (IRB Number: 2019-07) of the Research Institute of Tropical Medicine.

  • Open Access

    Efficacy and Safety of Makabuhay (Tinospora rumphii) 25% Cream Versus Hydrocortisone 1% Cream in the Management of Mosquito Bite Reactions: Randomized Double-Blind Controlled Trial (Preprint)

    by Julius Garcia Gatmaitan, Jolene Kristine Garcia Gatmaitan-Dumlao, Johannes Dayrit, Ma Teresita Gabriel

    BACKGROUND Most insect bite reactions resolve spontaneously, but the inflammation and pruritus induced have been shown to decrease the quality of life. Previous studies have shown the potential anti-inflammatory properties of Tinospora rumphii. OBJECTIVE The aim of the study is to assess the efficacy and safety of T rumphii 25% cream versus hydrocortisone 1% cream in the management of local cutaneous reactions caused by mosquito bites. METHODS This study was a parallel-group, double-blind, randomized, placebo-controlled trial with a 1-week duration in a span of 3 months (June 2019 to August 2019). Participants were exposed to sterile noninfectious mosquitoes (Aedes aegypti) for 5-10 minutes to elicit cutaneous lesions. Tinospora 25% cream or hydrocortisone 1% cream was applied twice daily throughout the 7-day study period. Of the 70 participants screened for this study, which was approved by an institutional review board (IRB 2019-07) at the Dermatology Outpatient Department of the Research Institute for Tropical Medicine, Alabang, Muntinlupa, Philippines, 58 participants in total met the inclusion criteria and were randomized to treatment (Tinospora: n=29) and active control (hydrocortisone: n=29) groups. RESULTS In total, 58 participants were randomized to receive Tinospora cream (n=29) or hydrocortisone cream (n=29). All participants completed the follow-up. There was a significant decrease in lesion size in both groups from the first 15 minutes to day 7 (P<.001). Comparing the lesion size in both groups, there was a statistically significant decrease in lesion size in the first hour (P=.003) and after 24 hours (P=.03). On day 1, 10% (n=29) of participants in the hydrocortisone group and 7% (n=29) in the Tinospora group experienced complete resolution. On day 3, all participants experienced complete resolution. No adverse effects were documented. CONCLUSIONS Tinospora 25% cream is safe, effective, and comparable to hydrocortisone 1% cream as an anti-inflammatory agent for mosquito bite reactions based on the decrease in lesion size, the proportion of participants with complete resolution of wheals, and improvement in pruritus intensity score using a visual analog scale. Long-term safety studies are recommended. CLINICALTRIAL Philippine Health Research Registry PHRR230716-005932; https://www.herdin.ph/index.php/registry?view=research&layout=details&cid=5932